# Gwalrus Biomaterials

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gwalrus-biomaterials

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.gwalrus.com
- Total disclosed funding: $14M
- Latest round: Series B (Jan 10, 2026)
- Investors on record: 1

## About

Based in Shanghai, China and founded in 2020, Shanghai Jinghai Gwalrus Biomaterials Co., Ltd., dba Gwalrus Biomaterials, focuses on creating biocompatible materials. The firm develops and produces advanced biocompatible materials aimed at supporting sustainability, particularly in line with China's dual carbon strategy. Its core offerings include materials for medical devices, packaging, and environmental solutions, which address challenges in waste management and carbon emissions. The revenue model of Gwalrus Biomaterials is built on B2B transactions, primarily involving direct sales to manufacturers and wholesalers.
In January 2026, Gwalrus Biomaterials closed nearly CNY 100 million in Series B funding.

## Funding rounds

- Series B, Jan 10, 2026, $14M — EPVC

## Investors

- EPVC (https://capitalatlas.ai/funds/epvc) — Series B